EGFR and non-small cell lung carcinoma: Moreover, the correlation between plasma ACh levels and EGFR-TKI response in human NSCLC patients suggests the ACh level in peripheral blood may predict clinical outcomes and help stratify patients to define an appropriate targeting strategy, although the origin of ACh in blood is diverse and remains to be elucidated.